Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dramatically improved hand hygiene performance rates at time of coronavirus pandemic.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020

Same author

A simplified blood culture sampling protocol for reducing contamination and costs: a randomized controlled trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019

Same author

Measles-related hospitalizations and associated complications in Jerusalem, 2018-2019.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019

Same author

Procalcitonin in hemodialysis patients presenting with fever or chills to the emergency department.

Internal and emergency medicine·2019

Same author

Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathy.

Clinical and experimental immunology·2018

Same author

Predictors for Adherence to Multidisciplinary Follow-Up Care after Sleeve Gastrectomy.

Obesity surgery·2018

Search research articles

Related Experiment Video

Updated: May 31, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Does CYP2C19 inhibition lead to clopidogrel thrombogenicity?

¹Division of Internal Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. matan123@hadassah.org.il

Medical Hypotheses

|July 2, 2011

Summary

The combination of clopidogrel and proton-pump inhibitors increases mortality. This drug interaction may stem from proton-pump inhibitors inhibiting CYP2C19, leading to harmful clopidogrel metabolites.

Area of Science:

Pharmacology
Clinical Medicine
Drug Metabolism

Background:

Concomitant use of clopidogrel and proton-pump inhibitors (PPIs) is common.
Concerns exist regarding potential adverse effects and drug interactions between clopidogrel and PPIs.
Previous studies suggest a possible reduction in clopidogrel's efficacy when used with PPIs.

Purpose of the Study:

To investigate the impact of the combined use of clopidogrel and PPIs on mortality.
To evaluate the hypothesis that PPIs increase mortality risk by altering clopidogrel metabolism.

Main Methods:

A meta-analysis of available mortality data was conducted.
Data were analyzed to compare mortality rates between patients using clopidogrel alone versus those using clopidogrel with PPIs.

More Related Videos

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: May 31, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

The role of CYP2C19 inhibition in the observed effects was considered.

Main Results:

The meta-analysis revealed that the mortality benefit of clopidogrel was significantly diminished in patients also taking PPIs.
Conversely, the mortality associated with the combination of clopidogrel and PPIs was found to be higher than the mortality prevented by clopidogrel alone.
This suggests a detrimental effect beyond simple reduced efficacy.

Conclusions:

The combination of clopidogrel and PPIs appears to increase mortality, a finding not adequately explained by reduced clopidogrel efficacy alone.
A proposed mechanism involves PPI-induced inhibition of CYP2C19, leading to the formation of thrombogenic clopidogrel metabolites.
Further research is warranted to elucidate the precise mechanisms and clinical implications of this drug interaction.